Legend Biotech (LEGN) Tops Q2 EPS by 9c

Legend Biotech (NASDAQ: LEGN) reported Q2 EPS of $0.16, $0.09 better than the analyst estimate of $0.07. Revenue for the quarter came in at $387.5 million versus the consensus estimate of $362.81 million.

For earnings history and earnings-related data on Legend Biotech (LEGN) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Lulu’s Fashion Lounge Holdings (LVLU) Misses Q2 EPS by 37c
• Epsilon Energy Ltd. (EPSN) Reports Q2 EPS of $0.23